PolyGen

PolygenRx is an Australian precision medicine biotechnology company that leverages advanced statistical genetics to optimize drug discovery and patient treatment matching. The company's core technology, the Pharmagenic Enrichment Score (PES) platform, integrates genome-wide association study (GWAS) data with individual genetic profiles to quantify the genetic burden within specific drug-responsive biological pathways. This approach allows for the stratification of patients in clinical trials, identifying those most likely to respond to specific therapies and potentially rescuing drug candidates that might otherwise fail due to population heterogeneity. PolygenRx is currently advancing programs in complex chronic conditions, including schizophrenia, bipolar disorder, and hypertension, with clinical trials scheduled to evaluate its genetically guided treatment plans.